Chemours (NYSE:CC) Stock Gets Price Target Reduction from JPMorgan Chase & Co.

Chemours (NYSE:CC) had its target price decreased by JPMorgan Chase & Co. from $15.00 to $14.00 in a research note published on Monday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the specialty chemicals company’s stock.

A number of other equities research analysts also recently issued reports on the stock. Truist Financial reduced their price target on shares of Chemours from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, November 4th. Royal Bank Of Canada cut Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target on the stock. in a report on Tuesday, October 13th. The Goldman Sachs Group restated a “neutral” rating and issued a $16.00 price target on shares of Chemours in a report on Friday, October 9th. UBS Group dropped their price objective on Chemours from $16.00 to $15.00 and set a “neutral” rating for the company in a research note on Wednesday, November 4th. Finally, Barclays initiated coverage on Chemours in a report on Monday, October 12th. They set an “equal weight” rating and a $16.00 price objective for the company. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.36.

Chemours Trading Up 1.9%

NYSE:CC opened at $13.73 on Monday. The stock has a fifty day moving average price of $13.84 and a two-hundred day moving average price of $18.18. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -13.47 and a beta of 1.47. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81. Chemours has a 1 year low of $10.44 and a 1 year high of $28.67.

Chemours (NYSE:CC) last released its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same period last year, the business posted $0.40 EPS. Chemours’s revenue was up 3.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Chemours will post 0.82 earnings per share for the current fiscal year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be paid a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s dividend payout ratio (DPR) is -34.31%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CC. Parallel Advisors LLC boosted its stake in shares of Chemours by 10.9% during the first quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock valued at $118,000 after acquiring an additional 527 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Chemours in the 2nd quarter valued at about $34,000. Allworth Financial LP acquired a new stake in shares of Chemours during the 2nd quarter worth about $51,000. State of Wyoming acquired a new stake in shares of Chemours during the 2nd quarter worth about $67,000. Finally, Corient Private Wealth LP boosted its stake in shares of Chemours by 12.6% during the 2nd quarter. Corient Private Wealth LP now owns 30,644 shares of the specialty chemicals company’s stock worth $629,000 after purchasing an additional 3,432 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Chemours

Here are a few of the latest headlines about CC:

• Neutral Sentiment: Investors bought 21,465 Chemours call options on Wednesday, about 633% above the average volume of 2,930. This indicates unusually active options trading, but does not establish a clear direction for the stock. No article link was provided.
• Negative Sentiment: Multiple law firms reminded investors that December 7, 2026 is the deadline to seek lead-plaintiff status in a securities class action covering purchases from February 20 to August 4, 2026. The complaint alleges Chemours misrepresented demand for its Opteon refrigerants, including that strong 2025 sales masked an overfilled distribution channel and weaker underlying demand. These are allegations, not proven findings; the litigation could add uncertainty and potential costs. Article: CC Shareholder Alert
• Negative Sentiment: JPMorgan issued a pessimistic forecast for Chemours shares, adding to bearish sentiment. The supplied article information does not specify its price target or rationale. Article: JPMorgan Chase Issues Pessimistic Forecast for Chemours

About Chemours

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.